Title

Authors

Document Type

Article

Department

Ophthalmology

Abstract

Two studies have shown that docetaxel-based regimens yield better survival, pain control, and quality of life for patients with advanced hormone-refractory prostate cancer than do mitoxantrone-based regimens.